Consumer Group to FDA: Pull Novo Nordisk A/S's Victoza Off the Market

Novo Nordisk A/S (NOVOB) said it rejects assertions by the U.S. group Public Citizen that the diabetes drug Victoza should be pulled from the market.

“Novo Nordisk is committed to patient safety and rejects Public Citizen’s assertion that the benefits of Victoza are outweighed by its risks,” the Bagsvaerd, Denmark-based company said in an e-mailed statement late yesterday.

Back to news